Osmol Therapeutucs, Inc. (New Haven, CT) is developing a therapy discovered at Yale University by Professor Barbara Ehrlich and licensed to the company for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) and Neurologic Impairment. Currently, there are no approved drugs for these indications. Osmol closed an initial Series A Preferred Stock financing at the end 2016 that was led by Elm Street Ventures and Koax Investment Partners. Further Series A closings took place in 2020 and included new investors. Bob Linke joined the company as President and CEO in 2020, replacing ESV Venture Partner Brian R. Dixon.